Is surgery essential for management of high grade neuroendocrine carcinoma of the breast? A case report and review

•High-grade neuroendocrine carcinoma of breast is a rare and aggressive malignancy.•HGNCB is managed similarly as traditional breast cancers.•Surgery has been the mainstay of treatment for traditional breast cancers.•Concurrent chemoradiation is a viable option for HGNCB.•Etoposide plus platinum is...

Full description

Saved in:

Bibliographic Details
Published in:	Current problems in cancer. Case reports Vol. 4; p. 100118
Main Authors:	Sudbeck, Dakota M, Mathew, Boban N
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01-12-2021 Elsevier
Subjects:	Breast cancer Concurrent chemoradiation Extrapulmonary small cell carcinoma Neuroendocrine carcinoma of breast Neuroendocrine carcinoma of breast Extrapulmonary small cell carcinoma HGNCB PCI EPSCC Breast cancer Concurrent chemoradiation SCCL
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•High-grade neuroendocrine carcinoma of breast is a rare and aggressive malignancy.•HGNCB is managed similarly as traditional breast cancers.•Surgery has been the mainstay of treatment for traditional breast cancers.•Concurrent chemoradiation is a viable option for HGNCB.•Etoposide plus platinum is an effective regimen for HGNCB, similar to SCCL. High grade neuroendocrine carcinoma of the breast (HGNCB) is an aggressive and rare primary breast malignancy. No standard management recommendations exist for this entity and they are managed similarly as traditional breast cancers. Here we present the first case of a 54 year old female with high grade neuroendocrine carcinoma of the breast managed non-surgically with concurrent chemoradiation. At the time of this publication, she is more than 8 years from diagnosis without evidence of recurrence.
ISSN:	2666-6219 2666-6219
DOI:	10.1016/j.cpccr.2021.100118